Alkacel Melphalan 2 mg (1 pack / 25 tabs)

Buy Alkacel 2 mg Melphalan Tablets Online

Alkacel Melphalan – 2 mg Tablets (1 pack / 25 tabs)

At a Glance

Generic Name: Melphalan

Brand Name: Alkacel

Strength & Pack Size: 2 mg tablets, 1 pack / 25 tabs

Dosage Form & Route: Oral tablets for swallowing with water

Therapeutic Class: Alkylating antineoplastic agent (nitrogen mustard derivative)

Primary Indications: Multiple myeloma and selected other haematologic or solid tumour protocols as per local label

Typical Use in Therapy: Part of induction, consolidation or palliative regimens, sometimes with steroids or other agents

Mode of Action: Cross-links DNA to inhibit replication and trigger cancer cell death

Key Benefits: Long-established backbone drug in multiple myeloma regimens with flexible oral dosing

Precautions: Myelosuppression, infection risk, nausea, fertility impact and potential long-term secondary malignancy risk

Storage: Store below 25 °C in original cytotoxic packaging, away from moisture and children

Product Description

Alkacel 2 mg contains melphalan, a classic alkylating agent used for decades in the treatment of multiple myeloma and certain other malignancies. This oral presentation provides 2 mg melphalan tablets in a 1 pack / 25 tabs format, allowing haematology–oncology teams to build precise daily or intermittent doses tailored to the treatment protocol and the individual patient’s condition. Alkacel is a cytotoxic medicine that must only be prescribed and supervised by specialists experienced in systemic chemotherapy.

In multiple myeloma, melphalan has historically been combined with drugs such as steroids and, in some settings, novel agents to achieve remission or disease control. While treatment paradigms have evolved to include proteasome inhibitors, IMiDs and monoclonal antibodies, melphalan remains relevant in certain oral combination regimens and in conditioning strategies, according to region and current guidelines. Alkacel 2 mg tablets provide a low-strength, tablet-based option that supports fine-tuning of melphalan dosage when oral therapy is chosen.

Generic Meds Mart offers Alkacel 2 mg melphalan tablets in original cytotoxic cartons or bottles from licensed manufacturers and distributors. Each pack is clearly labelled with the strength, tablet count, batch number and expiry date, enabling oncology pharmacies and clinics to verify authenticity and record lot details for pharmacovigilance. Outer shipping cartons are neutral and do not reference cancer, chemotherapy or melphalan, supporting privacy for patients and hospitals. Our role is restricted to access and logistics; all decisions about whether and how to use Alkacel belong to your treating team.

Key Uses

Within the framework of local approvals and current protocols, Alkacel 2 mg melphalan tablets are typically used for multiple myeloma in adults as part of systemic treatment plans. Melphalan may feature in oral combination regimens for patients who are not candidates for intensive transplant-based therapy, or it may be used in selected conditioning or cytoreductive schedules when an oral alkylating backbone is preferred.

Melphalan can also appear in regimens for certain other haematologic or solid tumours where older protocols remain in use or where local practice supports melphalan-based approaches. However, the most widely recognised indication for Alkacel 2 mg remains multiple myeloma, and any off-label use must be guided by a specialist who is fully familiar with the current evidence, alternatives and patient-specific risk factors.

How Melphalan Works in Chemotherapy

Melphalan, the active ingredient in Alkacel 2 mg tablets, is an alkylating agent derived from nitrogen mustard. Once in the body, melphalan forms highly reactive intermediates that bind to DNA, creating cross-links within and between DNA strands. These cross-links interfere with DNA replication and transcription, leading to faulty DNA repair and ultimately cell death, particularly in rapidly dividing cells such as malignant plasma cells in multiple myeloma.

As an S-phase–non-specific alkylating agent, melphalan exerts its effects throughout the cell cycle but is especially damaging when cells attempt to divide. This broad activity underpins its long-standing role in myeloma protocols. However, because normal rapidly dividing cells in the bone marrow, gastrointestinal tract and hair follicles may also be affected, careful dosing and monitoring are essential to balance efficacy and toxicity. Over time, exposure to alkylating agents such as melphalan can contribute to an increased risk of secondary malignancies, including therapy-related myelodysplastic syndromes and acute leukaemias, which is one reason specialist oversight is so important.

Dosage & Administration

Alkacel 2 mg melphalan tablets must never be used without a clear written regimen from a haematology–oncology specialist. Melphalan dosing is often based on body surface area, renal function, comorbidities, concomitant medicines, prior treatment history and overall treatment intent. Schedules can include continuous daily dosing, intermittent cycles, pulse dosing or combinations with steroids and other cytotoxic or targeted agents, depending on the protocol.

The 2 mg strength allows fine adjustments to the total daily dose; several tablets may be taken together to reach the prescribed amount. Tablets are usually swallowed whole with water and are not crushed or chewed due to the cytotoxic nature of the drug and the potential for altered absorption or increased exposure. Handling instructions, such as wearing gloves when splitting blister packs or avoiding direct contact with broken tablets, should follow local cytotoxic guidelines. If a dose is missed, patients must follow the specific instructions given by their treatment centre rather than taking extra tablets on their own initiative.

Precautions

Because melphalan is a potent myelosuppressive agent, close monitoring of full blood counts is essential during Alkacel therapy. Neutropenia, thrombocytopenia and anaemia are common and may require treatment delays, dose reductions, transfusions or growth factor support. Patients and caregivers should be aware of warning signs such as fever, sore throat, persistent cough, unexplained bruising, unusual bleeding or extreme fatigue, and should contact the treating team immediately if these occur.

Melphalan can also cause nausea, vomiting, diarrhoea, oral mucositis, hair thinning or loss and less commonly liver enzyme elevations or pulmonary toxicity. Renal impairment can alter drug handling, and dose adjustments may be needed in patients with reduced kidney function. Because melphalan is mutagenic and potentially carcinogenic, long-term use is associated with an increased risk of therapy-related myeloid malignancies. Alkacel is teratogenic and should not be used during pregnancy unless there are no alternatives and the potential benefit clearly outweighs the risk; effective contraception is recommended during treatment and for a period afterwards. Melphalan may affect fertility in all genders, so discussions about fertility preservation before starting therapy are important for many patients.

Melphalan Side Effects

Common side effects

Common melphalan side effects with Alkacel 2 mg tablets include bone marrow suppression with low white blood cells, red cells and platelets, increased susceptibility to infections, tiredness, weakness, nausea, vomiting, loss of appetite, mild diarrhoea or constipation, mouth soreness or ulcers, and hair thinning or partial hair loss. Some patients may notice mild skin changes or transient elevations in liver enzymes on blood tests.

These effects are often manageable with supportive measures such as antiemetics, mouth care routines, nutritional support, transfusions and growth-factor support where appropriate, combined with dose adjustments or schedule changes under specialist guidance. It is important not to stop melphalan tablets abruptly or change the dose without consulting the treating team, as they may be able to improve tolerability by modifying the regimen rather than discontinuing therapy entirely.

Serious side effects

Serious melphalan adverse effects require urgent medical attention. These can include severe or prolonged neutropenia with high fever or sepsis, severe thrombocytopenia with significant bleeding, profound anaemia causing chest pain or shortness of breath at rest, heavy or persistent gastrointestinal symptoms with dehydration, signs of liver injury such as jaundice and dark urine, new or worsening respiratory symptoms that could reflect pulmonary toxicity and, in the longer term, evidence of therapy-related myelodysplastic syndrome or acute leukaemia on blood or bone marrow tests.

If any of these serious warning signs appear during treatment with Alkacel 2 mg melphalan tablets, patients must seek emergency care and inform clinicians that they are receiving an alkylating agent. The haematology–oncology team may need to stop treatment, adjust doses, change regimens or introduce additional supportive therapies to manage complications.

Storage

Alkacel 2 mg melphalan tablets should be stored in their original cytotoxic packaging at a temperature specified in the product leaflet, generally below 25 °C, protected from moisture and direct heat. The pack should remain tightly closed when not in use, and tablets should only be removed immediately before dosing. As with all chemotherapy medicines, Alkacel must be kept out of the sight and reach of children and stored separately from everyday household medicines to prevent accidental ingestion. Unused or expired tablets and any materials contaminated with melphalan should be returned to a pharmacy or disposed of according to local hazardous or cytotoxic waste procedures, not in household rubbish.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to key oncology and haematology medicines such as Alkacel 2 mg melphalan tablets. We work only with licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice standards and can provide verifiable batch and documentation trails. Each pack of Alkacel 2 mg we supply is original, sealed and labelled with strength, batch number and expiry date so hospital and clinic pharmacies can confirm authenticity.

Displaying Alkacel prices in USD helps patients and treatment centres plan multi-cycle therapy budgets more easily. Neutral outer packaging protects privacy, and trackable delivery options, where regulations allow, make it simpler to coordinate medicine arrival with clinic visits, blood tests and treatment dates. Our service does not replace your haematologist or oncologist and does not include personalised medical advice; we support access and logistics while treatment decisions remain strictly between you and your specialist team.

Order Now

Alkacel 2 mg melphalan tablets are powerful cytotoxic medicines and must never be started, stopped or adjusted without direct instruction from an experienced haematology–oncology team. Before you or your clinic buy Alkacel online from Generic Meds Mart, your diagnosis, treatment goals, alternative options and overall health status should be fully reviewed with your specialist, and a clear melphalan dosage and monitoring plan should be agreed in writing.

Once this plan is in place, your team can calculate how many Alkacel 2 mg tablets and how many packs of 1 pack / 25 tabs are needed for the next phase of therapy, taking into account any planned dose adjustments or treatment breaks. The required quantity can then be selected on Generic Meds Mart, added to the cart and checked out in USD. Medicines will be shipped in discreet packaging, and all subsequent questions about melphalan dosage, melphalan side effects or regimen changes must be directed to your treating specialists rather than managed independently.

FAQ about Alkacel (Melphalan)

Q1: What is Alkacel 2 mg used for?
Alkacel 2 mg contains melphalan, an alkylating chemotherapy agent mainly used in multiple myeloma and selected other haematology or oncology protocols. It is usually part of combination regimens rather than a single stand-alone treatment, and its use is defined by specialist guidelines.

Q2: Is Alkacel taken every day?
The schedule for Alkacel 2 mg melphalan tablets depends on the protocol your haematologist chooses. Some regimens involve short courses on specific days of a cycle, while others may use more continuous dosing. Only your treating team can explain the exact plan for your situation and whether daily or intermittent dosing is appropriate.

Q3: Can Alkacel tablets be cut or crushed?
Because melphalan is a cytotoxic drug, Alkacel tablets are usually swallowed whole to limit exposure to the powder and to keep absorption predictable. You should not cut, crush or chew Alkacel 2 mg tablets unless your treatment centre gives explicit written instructions and appropriate handling advice. If swallowing tablets is difficult, discuss alternative strategies with your specialist.

Q4: What monitoring will I need while on Alkacel?
Patients on Alkacel melphalan typically require regular full blood counts, kidney and liver function tests, and clinical assessment for signs of infection, bleeding, mucositis or other toxicities. In long-term use, your team may also watch for signs of therapy-related myeloid malignancies. All required tests and visit intervals will be outlined in your treatment plan.

Q5: What should I do if I miss a dose of Alkacel?
If you miss a dose of Alkacel 2 mg melphalan tablets, do not double the next dose unless your haematology team explicitly instructs you to do so. Contact your treatment centre as soon as possible and follow their advice; they may adjust your schedule or ask you to skip the missed dose depending on where you are in the cycle.